Background -The aim of this study was to extend previous in vitro observations regarding the effects ofmultiple actuations of aerosols into spacer devices, delayed inhalation, and antistatic treatment of spacer devices on the amount of drug delivered for inhalation. An in vivo study of lung bioavailability of salbutamol from a large volume (Volumatic) spacer was conducted. Methods -Ten healthy volunteers of mean age 20.5 years with a mean forced expiratory volume in one second of 112.1% predicted were studied in a randomised single blind (investigator blind) crossover study. 1200 ig ofsalbutamol was given with mouth rinsing (100 tg/puff) on four study days: single puffs via spacer, multiple puffs via spacer (3 x 4 puffs), single puffs with 20 second delay before inhalation via spacer, and single puffs via an antistatic treated spacer. All spacers, including those treated with antistatic, were prewashed prior to each study day. Measurements oflung bioavailability were made at five, 10, and 20 minutes after inhalation to determine peak (Cmax) and average (Cav) plasma salbutamol levels. Systemic P2 responses including finger tremor, heart rate, and plasma potassium levels were also evaluated. (Thorax 1996;51:981-984) 
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Results -Single puffs from the spacer produced higher plasma Spacer devices are used to reduce the need for coordination and to increase drug deposition when inhaling drugs into the respiratory tract in the management of asthma.' They are also beneficial in reducing the local and systemic side effects of inhaled steroids.23 They are particularly useful in childhood asthma and the addition of a face mask allows them to be used for preschool children as an alternative to nebulisers. 4 A common concern amongst medical practitioners and parents of asthmatic children is that of the technique of using spacer devices which will reliably deliver inhaled medications in both normal use and in an acute asthma attack. For example, the parents of preschool children will often actuate a drug into a spacer device for the child and there may be a significant delay before the child then inhales from this. In vitro studies using the multistage liquid impinger model indicate that this delayed inhalation may significantly reduce the dose of drug delivered.5-7 The current British Thoracic Society guidelines recommend the administration of multiple actuations of 12 agonist from a spacer to patients as an alternative to a nebuliser,8 such as in the case of a general practitioner called to see a patient with an asthma attack. Again, in vitro work suggests that the dose of inhaled drug may be much lower than anticipated with the use of multiple rather than single puffs.5'-Another possible variable affecting lung bioavailability of medications from spacer devices is the degree of static charge of the spacer. Aerosol particles from a metered dose inhaler (MDI) are highly charged and therefore the higher the static charge on the walls of the spacer, the more likely it is that the drug will be deposited there and be unavailable for inhalation.57
The aim of this study was to examine the in vivo effects of these three variables on salbutamol lung bioavailability and associated systemic 12 responses as follows: (1) All blood samples were measured in batches at the end ofthe study and assayed in duplicate. Plasma potassium levels were measured by flame photometry using an IL943 analyser (Instrumentation Laboratory Ltd, Warrington, UK). The intra-assay and inter-assay values for analytical imprecision were 0.41% and 1.04%, respectively.
Plasma salbutamol levels were assayed by high performance liquid chromatography (HPLC) with solid phase extraction and fluorescence detection as previously described. The analytical imprecision for plasma salbutamol was 3.9% (intra-assay) and 4 . 1% (inter-assay) at 4 ng/ml, and 11.8% (intraassay) and 12.6% (inter-assay) at The ratio between single and multiple puffs for Cmax was 1.93-fold (95% CI 1.68 to 2.19). Single puffs produced significantly higher levels than multiple puffs for Cmax and Cav, and increased systemic P2 responses on tremor, heart rate, and potassium levels. Single puffs with delayed inhalation produced significant decreases in plasma salbutamol levels and in systemic effects on tremor and heart rate but not potassium levels. The ratio between single puffs and single puffs with delayed inhalation for Cmax was 1.80-fold (95% CI 1.59 to 2.00).
Single puffs from the standard spacer produced a significant increase in Cmax compared with the antistatic treated spacer (both prewashed) with a ratio of 1.23 (95% CI 1.04 to 1.41), although no other differences were seen in average plasma salbutamol levels or systemic 32 responses. to 1000 ,uglday since patients will in general be on the steep part of the dose-response curve for antiasthmatic efficacy.'2 A 20% difference in dose received could therefore have considerable impact on their disease control. It is also conceivable that patients could end up taking a greater number of puffs to achieve the same delivered dose, which will have significant long term cost and perhaps compliance implications. Another important issue is drug delivery during an acute asthma attack. Due to reduced airway calibre and reduced lung deposition during an asthma attack, patients are likely to be at the steep part of the dose-response curve for bronchodilator efficacy of salbutamol. Indeed, this is the rationale for using high nebulised doses of 32 agonist in this situation. As the use ofmultiple actuations in a spacer results in an approximate twofold reduction in the lung bioavailability of salbutamol, this should be taken into account in calculating the number ofpuffs required for acute bronchodilator relief.
We found that washing a Volumatic spacer is as effective as antistatic lining in reducing the effects of static charge on delivery of salbutamol in vivo. However, in vitro work with budesonide7 or sodium cromoglycate5 using the impinger method revealed that delivery of drug was more than doubled using a low static spacer compared with an unwashed new spacer. This highlights the importance of studying individual drugs and their various delivery devices, as it is not possible to extrapolate results from different studies.
The preparation and use of the Volumatic spacers during the study was intended to simulate what could be expected in normal clinical practice, since brand new spacers are not used each time a patient inhales their medication. Initially all the spacers were washed to try to reduce the effect of the high static charge which new spacers have been noted to carry,"3 as this may have reduced the amount of salbutamol recovered. Thus, for practical purposes a general practitioner who has a Volumatic spacer device for delivery of emergency high dose 132 agonist therapy should prewash the spacer before its first use to reduce its high initial static charge.
In conclusion, we found that variations in technique of inhaling salbutamol via a Volumatic spacer have a substantial impact on its lung bioavailability with regard to delay in inhalation and multiple actuations, whereas an antistatic coating had no additional effect compared with washing the spacer.
